Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-27
DOI
10.3389/fphar.2020.00794
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin
- (2019) Stijn W. van Beek et al. CLINICAL PHARMACOKINETICS
- Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data
- (2019) João A. Abrantes et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sub-therapeutic rifampicin concentration is associated with unfavourable tuberculosis treatment outcomes
- (2019) Geetha Ramachandran et al. CLINICAL INFECTIOUS DISEASES
- Individualised dosing algorithm and personalised treatment of high‐dose rifampicin for tuberculosis
- (2019) Robin J. Svensson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
- (2019) Budi O Susanto et al. CLINICAL INFECTIOUS DISEASES
- Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations
- (2018) Robin J Svensson et al. JOURNAL OF INFECTIOUS DISEASES
- A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
- (2015) Martin J. Boeree et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction
- (2015) Maxwell T. Chirehwa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability
- (2015) Lia Liefaard et al. THERAPEUTIC DRUG MONITORING
- Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
- (2014) Abdullah Alsultan et al. DRUGS
- Between-subject variability: should high be the new normal?
- (2014) Hesham S. Al-Sallami et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
- (2013) J. G. Pasipanodya et al. JOURNAL OF INFECTIOUS DISEASES
- A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients
- (2012) Wynand Smythe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safe and Effective Variability—A Criterion for Dose Individualization
- (2012) Nicholas H.G. Holford et al. THERAPEUTIC DRUG MONITORING
- TheSLCO1B1rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
- (2011) Emmanuel Chigutsa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations
- (2010) M. Weiner et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information
- (2009) Johan E. Wallin et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia
- (2008) Guowei Dai et al. JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started